Etanercept therapy allows the tapering of methotrexate and sustained clinical responses in patients with moderate to severe psoriasis

Authors

  • Paul S. Yamauchi MD, PhD,

    1. From the Dermatology Institute and Skin Care Center, Santa Monica, and Division of Dermatology, David Geffen School of Medicine at UCLA, Los Angeles, California
    Search for more papers by this author
  • Nicholas J. Lowe MD

    1. From the Dermatology Institute and Skin Care Center, Santa Monica, and Division of Dermatology, David Geffen School of Medicine at UCLA, Los Angeles, California
    Search for more papers by this author


Paul S. Yamauchi, md, phd Dermatology Institute and Skin Care Center 2001 Santa Monica Blvd., Suite 490W Santa Monica, CA 90404
E-mail: psyamauchi@earthlink.net

Abstract

Methotrexate, the most common systemic small molecule used in the treatment of moderate to severe psoriasis, is associated with significant toxicities and adverse events. Long-term continuous usage is not recommended due to potential liver toxicity, myelosuppression, and other side effects. Abrupt cessation of methotrexate without tapering can lead to flare-up and rebound of psoriasis. Here we describe sustained clinical responses in 6 patients with psoriasis following gradual cessation of methotrexate through the addition of etanercept therapy.

Ancillary